Rationale for TOTAL trial: randomized trial of routine aspiration ThrOmbecTomy with PCI vs. PCI ALone in patients with STEMI undergoing primary PCI Sanjit.

Slides:



Advertisements
Similar presentations
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
Advertisements

Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
TOTAL Culprit lesion thrombus burden after manual aspiration thrombectomy or PCI alone in STEMI The OCT Substudy of the TOTAL (ThrOmbecTomy versus PCI.
on behalf of the TOTAL Investigators
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
‘SMASH IT!’ Mark Mason Interventional Cardiologist Harefield Hospital
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Results of CRYSTAL AMI: A Pilot Trial Before INFUSE AMI, the Concept and Evolution in Thrombus Management Saihari Sadanandan, MD, FACC, FASE, Dip. CBNC,
Clinical Trial Results. org C. Michael Gibson, M.S., M.D. Director TIMI Data Coordinating Center Invasive Cardiologist Beth Israel Deaconess Medical Center.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
Athens Cardiology Update CADILLAC Study Blood Transfusion after Myocardial Infarction: Friend, Foe or double-edged Sword? Georgios I. Papaioannou,
Improving outcome of STEMI PCI: Preliminary Results of Crystal AMI trial Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
on behalf of the TOTAL Investigators
A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.
For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2013 Medtronic, Inc. All rights reserved. UC ML.
Door to Balloon Time: Does it Matter? Tale of Two Studies.
Trial Vignettes 1-3 Mark Mason Harefield Hospital Royal Brompton and Harefield NHS Trust.
The MASTER Trial A Prospective, Randomized, Multicenter Evaluation of a PET Micronet Mesh Covered Stent (MGuard) in STEMI Sigmund Silber, MD, PhD FESC,
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
血栓吸栓:所有 STEMI 都需要吗? -TOTAL 研究的回答 徐亚伟 同济大学附属第十人民医院.
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD Thomas Stiermaier, MD; Suzanne.
M-Guard stent in STEMI patients with high thrombus burden lesions Mahmoud Shabestari Baktash Bayani Ali Eshraghi Bahram Shahri Mashhad University.
Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL) Stefan James Professor of Cardiology Uppsala Clinical.
Total Occlusion Study of Canada (TOSCA-2) Trial
Pros and Cons of Radial Access
CART-CL: Clinical and Research Update
Impact of Radial Access on Bleeding
Updates From NOTION: The First All-Comer TAVR Trial
Improving Outcomes in Cardiogenic Shock
Critical Appraisal of the European CAS Trials
PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)
Recent Breakthroughs in Cardiovascular Outcomes Trials in T2DM
Revascularization in Patients With Left Ventricular Dysfunction:
Why Radial Access Should be the Default for Women undergoing PCI?
The TREAT Study: Can Devices Lower Bleeding Rates?
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
On-Site Surgical Back-up is ‘Critically’ Important for PCI!
Kirk N Garratt MSc MD FSCAI
A prospective, randomized trial of
Uppsala Clinical Research Center
Presenter Disclosure Information
Is There a Role for Aspiration in STEMI?
Radial vs Femoral Access in ACS Patients
Seeking the Optimal Upstream Therapy for Patients with ACS: Fondaparinux- Low Bleeding Rate and Low Cost Sanjit S. Jolly MD, Interventional Cardiologist,
Study Design AMI <12 hours, any age, cardiogenic shock excluded
Valsartan in Acute Myocardial Infarction Trial Investigators
The ANTARCTIC investigators
ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
European Society of Cardiology 2003
Modified Rankin score 0-2
Dean J. Kereiakes et al. JACC 2017;70:
For the HORIZONS-AMI Investigators
A Systematic Review and Meta-analysis of Randomized Trials of Manual Thrombectomy in ST elevation myocardial infarction Investigators: Ashraf Alazzoni,
American College of Cardiology Presented by Dr. Michel R. Le May
RIDDLE-NSTEMI Trial design: Patients with NSTEMI were randomized to either immediate (within 2 hours) intervention or delayed (within 72 hours) intervention.
Global Registry of Acute Coronary Events: GRACE
Impedence-guided management
Mancini JG, et al. Am J Cardiol.
Ischemic Postconditioning
Maintenance of Long-Term Clinical Benefit with
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.
GUSTO 1 Trial 41,000 patients enrolled, landmark study
CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.
Presentation transcript:

Rationale for TOTAL trial: randomized trial of routine aspiration ThrOmbecTomy with PCI vs. PCI ALone in patients with STEMI undergoing primary PCI Sanjit Jolly MD MSc, FRCP(C) Assistant Professor, Interventional Cardiologist McMaster University Hamilton, Canada

Disclosures Received Grant Support from Medtronic Received Speakers honoria from GlaxoSmithKline, Sanofi-Aventis,Astra Zeneca, Boehringer Ingelheim

Epicardial flow is important However, 94% of patients achieve TIMI 3 flow after PPCI Stone GW, et al. JACC 2002;39:591-7.

Microvascular dysfunction in patients with normal epicardial flow 29% of patients with TIMI 3 flow have reduced microvascular perfusion (Myocardial blush grade <3) after PPCI Stone GW, et al. JACC 2002;39:591-7.

Review of three largest trials of Thrombectomy

AIMI Trial: Mechanical Thrombectomy increased infarct size and mortality P=0.03 Ali, A, et al. JACC.2006;48:244-.252.

TAPAS trial : Benefit for Surrogate outcome Single center trial of Thrombectomy (Export) vs. PCI alone during PPCI (N=1071) Benefit for primary outcome of myocardial blush grade 0 or 1 (poor microvascular flow) P<0.001 Svilaas T, et al. N Engl J Med. 2008;358:557-67.

Unexpected Reduction in Mortality at 1 year Trend at 30 days became significant at 1 year Experts cautioned that a large confirmatory trial is needed (small trials with unexpected large effect sizes, need to be replicated)

JET STENT: No difference in Infarct Size, mortality with mechanical thrombectomy P=0.40 P=ns Migliorini, A, et al. JACC. 2010;56:1298.

How do we explain conflicting results? Different thrombectomy devices have different clinical effects More likely: Small trials with few events unreliable A large scale definitive trial is needed

Stroke: Risk of Harm Trend toward increased risk of stroke with devices 1.9% vs. 0.3% RR 3.43 (95% CI 0.85-13.9), p=0.085 Emphasizes the need for a definitive multicenter trial Bavry et al. Eur Heart J. 2008. 29;2989-3001.

Paradigm Does removal of thrombus during PPCI improve clinical outcomes? Unanswered question: We have the opportunity to answer

Thrombectomy use only 4% of PPCI in USA Data from ACC NDR registry of 217,355 primary PCI procedures

International STEMI survey 27 item online survey (Survey MonkeyTM) Distributed to various investigator networks in North America, Europe and Asia and members of Canadian Association of Interventional Cardiology Received 477 responses (response rate 29%) Russo J, et al. Circulation. 2010. AHA abstract

Routine Use of Aspiration thrombectomy during PPCI Only 36% use aspiration thrombectomy routinely with no significant variation by region

Have you ever experienced a complications related to Aspiration Thrombectomy? 1 in 5 interventionalists have experienced a serious complication related to thrombectomy

Existing evidence supports universal AT use Need for a large RCT Existing evidence supports universal AT use 21% agree A large, definitive AT trial is needed 85% percent of respondents would randomize patient s 89% agree

Summary Thrombectomy is not used routinely by majority of operators during PPCI TAPAS trial was promising but far from definitive Large multicenter randomized trial needed to determine benefits of routine thrombectomy on clinical outcomes

TOTAL Trial N=4000 Primary outcome: CV death, recurrent MI, cardiogenic shock and new or worsening NYHA Class IV HF at 180 days Contact email: total@phri.ca Supported by Canadian Network and Center for Trials internationally and Medtronic

TOTAL trial Potential to be a landmark trial in STEMI Validate concept that thrombus removal improves clinical outcomes Lead to other breakthroughs in STEMI care If interested in partcipating contact email: total@phri.ca